CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA
The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Zefylti®, its filgrastim biosimilar version. Earlier in February 2025, Zefylti® received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ’s second biosimilar to be approved by MHRA after the approval of Bevqolva® in December 2024.
About the Company
Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercialises a wide range of generic pharmaceuticals, branded speciality pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
The company has 30+ manufacturing and packaging facilities that are approved by leading regulatory agencies, including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
Disclaimer: The article is for informational purposes only and not investment advice.